Longeveron's ELPIS II Trial Misses Primary Endpoint; Company Launches Strategic Review
LGVN sits 41% above its 52-week low of $4.75.
Summary
Longeveron's Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome failed its primary endpoint, with a least-squares mean difference in RVEF of −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336). The company is now exploring all options to maximize shareholder value, including engaging an investment bank and implementing cost containment. This is a major setback for the lead pediatric program, though the company highlights exploratory signals like 31% fewer MACE events (12 vs. 19) and no deaths in the treated arm, while one control group patient died over 12 months. With a market cap around $21 million and cash runway only into Q4 2026, the strategic review signals potential restructuring or sale. Investors should watch for FDA discussions and any strategic transaction announcements.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — On September 16, 2026, Longeveron announced ELPIS II missed its primary endpoint, with a least-squares mean difference in RVEF of −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336).
- Primary Endpoint — Primary endpoint mean difference was -0.7 percentage points (95% CI: -7.3 to 5.9).
- Safety — One control group patient died over 12 months, compared to no deaths in treated arm. TEAEs: 94.1% (treated) vs. 100% (control); TE-SAEs: 64.7% (treated) vs. 71.4% (control). No TEAEs or TE-SAEs were assessed as related to laromestrocel by investigators.
- Efficacy
- Transplant-free survival: 1 event (17 treated) vs. 2 events (21 control) over 5 years.
- Hospitalization burden was similar between the treated and control arms.
- MACE events were 31% fewer in treated arm (12 vs. 19), but not statistically significant.
- Exploratory hierarchical composite endpoint was not statistically significant.
- Regulatory Context — FDA previously advised RVEF alone would not be sufficient for regulatory approval.
- Trial Design
- ELPIS II trial collaborated with NHLBI through NIH grants (Award Number UH3HL148318).
- 40 infants randomized 1:1 to single intramyocardial dose during Stage 2 palliative surgery.
- Stage 2 palliative surgery was bidirectional Glenn or hemi-Fontan procedure.
- Long-term follow-up for transplant-free survival is planned for up to 5 years.
- Primary endpoint (RVEF) was assessed by cardiac magnetic resonance (CMR).
- ELPIS II is a Phase 2b, randomized, double-blind, multicenter, two-arm trial.
- Control arm received standard of care surgery alone.
All 17 details
- Primary endpoint mean difference was -0.7 percentage points (95% CI: -7.3 to 5.9).
- One control group patient died over 12 months, compared to no deaths in treated arm.
- Transplant-free survival: 1 event (17 treated) vs. 2 events (21 control) over 5 years.
- Hospitalization burden was similar between the treated and control arms.
- MACE events were 31% fewer in treated arm (12 vs. 19), but not statistically significant.
- Exploratory hierarchical composite endpoint was not statistically significant.
- TEAEs: 94.1% (treated) vs. 100% (control); TE-SAEs: 64.7% (treated) vs. 71.4% (control).
- No TEAEs or TE-SAEs were assessed as related to laromestrocel by investigators.
- FDA previously advised RVEF alone would not be sufficient for regulatory approval.
- ELPIS II trial collaborated with NHLBI through NIH grants (Award Number UH3HL148318).
- 40 infants randomized 1:1 to single intramyocardial dose during Stage 2 palliative surgery.
- Stage 2 palliative surgery was bidirectional Glenn or hemi-Fontan procedure.
- Long-term follow-up for transplant-free survival is planned for up to 5 years.
- Primary endpoint (RVEF) was assessed by cardiac magnetic resonance (CMR).
- ELPIS II is a Phase 2b, randomized, double-blind, multicenter, two-arm trial.
- ELPIS II ClinicalTrials.gov identifier is NCT04925024.
- Control arm received standard of care surgery alone.
At the time of this announcement, LGVN was trading at $6.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.3M. The 52-week trading range was $4.75 to $12.30. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.